LOS ANGELES (Reuters) - A team of doctors and scientists using artificial intelligence (AI) for the first time have discovered two heart defects that are often overlooked by experts.
One is hypertrophic cardiomyopathy and the other is cardiac amyloidosis, both of which are fatal.
A team of scientists and doctors at the Cedar Sinai Smt Heart Institute in Los Angeles have discovered two heart conditions with the help of artificial intelligence, the record of which has been published in the Journal of the American Medical Association.
The head of the team, David Owing, says it takes years and even decades for patients with these diseases to be properly diagnosed. Now, thanks to AI, the disease has been diagnosed by looking at specific patterns because the human eye could not see it.
In a two-stage identification process, 34,000 heart ultrasound videos have been tested on a special algorithm. These videos were taken from hospitals and other institutions. During this time the software was trained to see the different symptoms of the disease. These included the area of the heart cells, the thickness of the heart wall and other information. The software specifically notes these two conditions and tells the doctors.
The software worked like a master doctor because it was also noting changes that were initially too small to be hidden from the doctor. Then the disease was diagnosed very accurately without any test which is a great development.
The reason is that scientists have been calling these changes, such as the thickness of the heart walls, changes with age. Algorithm software can also identify normal and abnormal heart. In this way, the lives of many patients can be saved by early identification.
Both hypertrophic cardiomyopathy and cardiac amyloidosis are fatal and progress slowly. That is why they are so difficult to identify.
Accurately identifying diseases thanks to artificial intelligence is a welcome thing that will save many lives. However, in the next phase, this algorithm will be tested on a large number of patients, which will reveal its further usefulness or reduction.
